MarketPulse

R&D investment

3 articles
The Motley FoolThe Motley Fool··Selena Maranjian

Eli Lilly's Weight-Loss Dominance and Cancer Pipeline Justify Premium Valuation

Eli Lilly shows 43% revenue growth and 51% EPS growth, backed by weight-loss drug leadership and $7B cancer acquisition. Forward P/E of 40 remains below historical average.
LLYvaluationearnings growth
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Proleukin Market Set to Expand 6.1% Annually Through 2030 Amid Cancer, CF Growth

Proleukin market projected to grow 6.1% annually to $1.68M by 2030, driven by rising cancer prevalence and expanded indications. Iovance Biotherapeutics strengthens position via 2023 acquisition.
NVSIOVAcancer treatmentcystic fibrosis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Decent Holding Posts Double-Digit Revenue Growth but Swings to Loss on Expense Surge

Decent Holding posts 12.2% revenue growth but swings to $322K loss as expenses surge 21.7% and margins compress.
DXSTnet lossrevenue growth